Perrigo announced that it has received approval from the FDA for its Abbreviated New Drug Application (ANDA) to market over-the-counter Nicotine Polacrilex Mini Lozenge, the generic version of GlaxoSmithKline‘s Nicorette Mini Lozenge.
Nicorette is indicated to reduce withdrawal symptoms, including nicotine craving, associated with quitting smoking. Nicotine replacement therapy releases small, stable amounts of nicotine into the body to alleviate cravings and withdrawal symptoms.
Nicotine Polocrilex will be available as mint flavor mini lozenges in 2mg and 4mg strengths. The product is expected to begin shipping in the next 90 days.
For more information call (866) 634-9120 or visit www.perrigo.com.